PMI will pay Altria Group nearly $2.7 billion for exclusive U.S. commercialization rights to IQOS.Read More
Tags :altria
Altria stock has increased 8 percent over the past month and is up 10 percent since an early-July low.Read More
Altria had published three related applications that focus explicitly on the cannabis plant.Read More
A design change, however, would require re-authorization from the U.S. Food and Drug Administration.Read More
The firm pulled its e-cigarettes because they were bad, not because of a side deal with Juul, company says.Read More
Critics say industry involvement will exacerbate public health harms. Read More
Atria wants the FDA's help in convincing Americans that nicotine isn't linked to cancer, a letter states.Read More
The cease and desist letter demands that stores and chains remove vape products made by Juul and others.Read More
The Altria Group said the authorization follows the FDA's review of the IQOS 3 PMTA.Read More
Altria does not currently intend to exercise its additional governance rights obtained upon conversion.Read More
